Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Cho R. Hong"'
Autor:
Stephen M.F. Jamieson, Peter Tsai, Maria K. Kondratyev, Pratha Budhani, Arthur Liu, Neil N. Senzer, E. Gabriela Chiorean, Shadia I. Jalal, John J. Nemunaitis, Dennis Kee, Avik Shome, Way W. Wong, Dan Li, Nooriyah Poonawala-Lohani, Purvi M. Kakadia, Nicholas S. Knowlton, Courtney R.H. Lynch, Cho R. Hong, Tet Woo Lee, Reidar A. Grénman, Laura Caporiccio, Trevor D. McKee, Mark Zaidi, Sehrish Butt, Andrew M.J. Macann, Nicholas P. McIvor, John M. Chaplin, Kevin O. Hicks, Stefan K. Bohlander, Bradly G. Wouters, Charles P. Hart, Cristin G. Print, William R. Wilson, Michael A. Curran, Francis W. Hunter
Publikováno v:
JCI Insight, Vol 8, Iss 4 (2023)
Externí odkaz:
https://doaj.org/article/b8265d5c0ed44e2583f6823d2b9a7cc0
Autor:
Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, Michael P. Hay
Publikováno v:
Molecules, Vol 28, Iss 11, p 4457 (2023)
The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target. Radiotherapy innovations such as stereotactic body radiother
Externí odkaz:
https://doaj.org/article/4764aa3eb15346ccaeda89c53387ec2a
Publikováno v:
Molecules, Vol 27, Iss 3, p 812 (2022)
Hypoxia in tumors results in resistance to both chemotherapy and radiotherapy treatments but affords an environment in which hypoxia-activated prodrugs (HAP) are activated upon bioreduction to release targeted cytotoxins. The benzotriazine 1,4-di-N-o
Externí odkaz:
https://doaj.org/article/f323dafd9c1d4eedae6a9fbb0c37c953
Autor:
Cho R. Hong, Gib Bogle, Jingli Wang, Kashyap Patel, Frederik B. Pruijn, William R. Wilson, Kevin O. Hicks
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Intra-tumor heterogeneity represents a major barrier to anti-cancer therapies. One strategy to minimize this limitation relies on bystander effects via diffusion of cytotoxins from targeted cells. Hypoxia-activated prodrugs (HAPs) have the potential
Externí odkaz:
https://doaj.org/article/764b9ed66dd64296903affcf0c72e274
Autor:
Hay, Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, Michael P.
Publikováno v:
Molecules; Volume 28; Issue 11; Pages: 4457
The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target. Radiotherapy innovations such as stereotactic body radiother
Autor:
Gib Bogle, William R. Wilson, Michael P. Hay, Praju Vikas Anekal, Kevin O. Hicks, Benjamin D. Dickson, Way W. Wong, Chantal D. Buckley, Cho R. Hong
Publikováno v:
Radiotherapy and Oncology. 166:162-170
Background and purpose Inhibitors of DNA-dependent protein kinase (DNA-PK) are effective radiation sensitisers in preclinical tumours, but little is known about risks of normal tissue radiosensitisation. Here, we evaluate radiosensitisation of head a
Autor:
William R. Wilson, Moana Tercel, Kevin O. Hicks, Frederik B. Pruijn, Sunali Mehta, Sarah P. McManaway, H. D. Sarath Liyanage, Cho R. Hong, Gib Bogle, Jagdish K. Jaiswal, Ho H. Lee
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:673-687
Hypoxia-activated prodrugs (HAPs) have the potential for eliminating chemo- and radiation-resistant hypoxic tumour cells, but their activity is often compromised by limited penetration into hypoxic zones. Nitrochloromethylbenzindoline (nitroCBI) HAPs
Publikováno v:
Molecules, Vol 27, Iss 812, p 812 (2022)
Molecules; Volume 27; Issue 3; Pages: 812
Molecules; Volume 27; Issue 3; Pages: 812
Hypoxia in tumors results in resistance to both chemotherapy and radiotherapy treatments but affords an environment in which hypoxia-activated prodrugs (HAP) are activated upon bioreduction to release targeted cytotoxins. The benzotriazine 1,4-di-N-o
Autor:
Peter Tsai, Fanying Meng, William R. Wilson, Purvi M. Kakadia, Jules B. L. Devaux, Cristin G. Print, Stefan K. Bohlander, Charles P. Hart, Aziza Khan, Zvi Shalev, Cho R. Hong, Troy Ketela, Bradly G. Wouters, Indumati Sharma, Stefano Marastoni, Francis W. Hunter, Anthony J. R. Hickey
Publikováno v:
Molecular Pharmacology. 95:638-651
Evofosfamide (TH-302) is a hypoxia-activated DNA-crosslinking prodrug currently in clinical development for cancer therapy. Oxygen-sensitive activation of evofosfamide depends on one-electron reduction, yet the reductases that catalyze this process i
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 2, Pp 159-171 (2019)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Tumor hypoxia contributes to resistance to anticancer therapies. Hypoxia-activated prodrugs (HAPs) selectively target hypoxic cells and their activity can extend to well-oxygenated areas of tumors via diffusion of active metabolites. This type of bys